Search

Your search keyword '"García‐Azorín, David"' showing total 450 results
Start Over Author "García‐Azorín, David"
450 results on '"García‐Azorín, David"'

3. Factors associated to the presence of headache in patients with influenza infection and its consequences: a 2010–2020 surveillance-based study

Author

García-Azorín, David, Santana-López, Laura, Lozano-Alonso, José Eugenio, Ordax-Díez, Ana, Vega-Alonso, Tomas, Macias Saint-Gerons, Diego, González-Osorio, Yésica, Rojo-Rello, Silvia, Eiros, José M., Sánchez-Martínez, Javier, Sierra-Mencía, Álvaro, Recio-García, Andrea, Martín-Toribio, Alejandro, Sanz-Muñoz, Ivan, and Guerrero-Peral, Ángel Luis

Published
2024
Full Text
View/download PDF

5. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Author

Obach, Victor, Velasco, Fernando, Alvarez Escudero, Rocio, Martín Bujanda, María, Aranceta, Sonsoles, Fabregat, Neus, Marco, Teresa, Ruisanchez, Aintzine, Roncero, Natalia, Mínguez-Olaondo, Ane, Ruibal, Marta, Guisado-Alonso, Daniel, Moreira, Antia, Cuadrado-Godia, Elisa, Echeverria, Amaya, Kortazar Zubizarreta, Izaro, López-Bravo, Alba, Riesco, Nuria, González-Fernández, Lucia, Pola, Nuria, Manera, Paula, Guerrero-Peral, Ángel Luis, Oterino Duran, Agustín, González-Osorio, Yésica, Armand, Rosario, Fernández-Fernández, Santiago, García-Azorín, David, and García-Moncó, Juan Carlos

Published
2023
Full Text
View/download PDF

8. Management of Headache Related to COVID-19

Author

Garcia-Azorin, David, Díaz de Terán, Javier, González-Quintanilla, Vicente, Gago-Veiga, Ana Beatriz, González-Martínez, Alicia, Echavarría-Íñiguez, Ana, Guerrero Peral, Ángel Luis, Martelletti, Paolo, Series Editor, Özge, Aynur, editor, Uludüz, Derya, editor, Bolay, Hayrunnisa, editor, and Karadaş, Ömer, editor

Published
2023
Full Text
View/download PDF

10. Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition

Author

Frontera, Jennifer A., Guekht, Alla, Allegri, Ricardo F., Ashraf, Mariam, Baykan, Betül, Crivelli, Lucía, Easton, Ava, Garcia-Azorin, David, Helbok, Raimund, Joshi, Jatin, Koehn, Julia, Koralnik, Igor, Netravathi, M., Michael, Benedict, Nilo, Annacarmen, Özge, Aynur, Padda, Karanbir, Pellitteri, Gaia, Prasad, Kameshwar, Romozzi, Marina, Saylor, Deanna, Seed, Adam, Thakur, Kiran, Uluduz, Derya, Vogrig, Alberto, Welte, Tamara M., Westenberg, Erica, Zhuravlev, Dmitry, Zinchuk, Mikhail, and Winkler, Andrea S.

Published
2023
Full Text
View/download PDF

13. Incidence and prevalence of headache in influenza: A 2010–2021 surveillance‐based study

Author

García‐Azorín, David, primary, Santana‐López, Laura, additional, Ordax‐Díez, Ana, additional, Lozano‐Alonso, José Eugenio, additional, Macias Saint‐Gerons, Diego, additional, González‐Osorio, Yésica, additional, Rojo‐Rello, Silvia, additional, Eiros, José M, additional, Sánchez‐Martínez, Javier, additional, Sierra‐Mencía, Álvaro, additional, Recio‐García, Andrea, additional, Guerrero‐Peral, Ángel Luis, additional, and Sanz‐Muñoz, Ivan, additional

Published
2024
Full Text
View/download PDF

18. Long COVID headache

Author

Tana, Claudio, Bentivegna, Enrico, Cho, Soo-Jin, Harriott, Andrea M., García-Azorín, David, Labastida-Ramirez, Alejandro, Ornello, Raffaele, Raffaelli, Bianca, Beltrán, Eloísa Rubio, Ruscheweyh, Ruth, and Martelletti, Paolo

Published
2022
Full Text
View/download PDF

20. Acute and Preventive Treatment of COVID-19-Related Headache: A Series of 100 Patients.

Author

García-Azorín, David, García-Ruiz, Claudia, Sierra-Mencía, Álvaro, González-Osorio, Yésica, Recio-García, Andrea, González-Celestino, Ana, García-Iglesias, Cristina, Planchuelo-Gómez, Álvaro, Íñiguez, Ana Echavarría, and Guerrero-Peral, Ángel L.

Subjects
*BOTULINUM toxin, *DRUG therapy, *BOTULINUM A toxins, *ANTI-inflammatory agents, *MIGRAINE, *IBUPROFEN
Abstract

To describe the need and effectiveness of acute and preventive medications in a series of 100 consecutive patients referred due to COVID-19-related headaches. Patients were aged 48.0 (standard deviation (SD): 12.4), 84% were female, and 56% had a prior history of headache. The most common headache phenotype was holocranial (63%), frontal (48%), pressing (75%), of moderate intensity (7 out of 10), and accompanied by photophobia (58%). Acute medication was required by 93%, with paracetamol (46%) being the most frequently used drug, followed by ibuprofen (44%). The drugs with the highest proportion of a 2 h pain-freedom response were dexketoprofen (58.8%), triptans (57.7%), and ibuprofen (54.3%). Preventive treatment was required by 75% of patients. The most frequently used drugs were amitriptyline (66%), anesthetic blockades (18%), and onabotulinumtoxinA (11%). The drugs with the highest 50% responder rate were amitriptyline (45.5%), mirtazapine (50%), and anesthetic blockades (38.9%). The highest 75% responder rate was experienced following onabotulinumtoxinA (18.2%). In conclusion, most patients required acute medication, with triptans and non-steroidal anti-inflammatory drugs achieving the best responses. Three-quarters of patients required preventive medication. The most frequently used drug was amitriptyline, which obtained the best results. In some treatment-resistant patients, anesthetic blockades and onabotulinumtoxinA were also beneficial. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study

Author

Gago‐Veiga, Ana Beatriz, primary, Lopez‐Alcaide, Noelia, additional, Quintas, Sonia, additional, Fernández Lázaro, Iris, additional, Casas‐Limón, Javier, additional, Calle, Carlos, additional, Latorre, Germán, additional, González‐García, Nuria, additional, Porta‐Etessam, Jesús, additional, Rodriguez‐Vico, Jaime, additional, Jaimes, Alex, additional, Gómez García, Andrea, additional, García‐Azorín, David, additional, Guerrero‐Peral, Ángel Luis, additional, Sierra, Álvaro, additional, Lozano Ros, Alberto, additional, Sánchez‐Soblechero, Antonio, additional, Díaz‐de‐Teran, Javier, additional, Membrilla, Javier A., additional, Treviño, Cristina, additional, and Gonzalez‐Martinez, Alicia, additional

Published
2024
Full Text
View/download PDF

24. Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions

Author

Thakur, Kiran T., Tamborska, Arina, Wood, Greta K., McNeill, Emily, Roh, David, Akpan, Imo J., Miller, Eliza C., Bautista, Alyssa, Claassen, Jan, Kim, Carla Y., Guekht, Alla, Pardo, Carlos A., Williams, Olajide, García-Azorín, David, Prasad, Kameshwar, Schmutzhard, Erich, Michael, Benedict D., Chou, Sherry H.-Y., Winkler, Andrea S., Solomon, Tom, and Elkind, Mitchell S.

Published
2021
Full Text
View/download PDF

25. Neurological presentations of COVID-19: Findings from the Spanish Society of Neurology neuroCOVID-19 registry

Author

Fernández, Alejandra Collía, Horga, Alejandro, Prieto, Ana Barragán, del Villar Igea, Ana, Núñez, Ana Urbanos, Serrano, Ángel Aledo, García, Araceli, Menéndez, Beatriz Martínez, Recasens, Bernat Bertran, Serrano, Blanca Serrano, de la Esperanza, Blanca Talavera, de la Hoz, Carlos Pablo de Fuenmayor Fernández, Juste, Carlos Tejero, Martín, Carmen Valderrama, García, Cristina Fernández, Ochoa, Marta, Íñiguez, Cristina, García, Daniel Macías, Pérez Martínez, David A., Santacruz, Débora Mª. Cerdán, Robert, Misericòrdia Floriach, Gomez, Elisabet Franquet, Puiggròs, Elsa, Álvarez, Eric Freire, Llamas, Esteban Peña, Villareal, Estibaliz, Díaz, Eva Fernández, Burguillos, Fernando Morejón, Beitia, Garazi Agirre, Gutiérrez-Gutiérrez, Gerardo, Monteiro, Guilherme Carvalho, Ygual, Guillermo Cervera, Hernández, Guillermo, Rubio, Guillermo, Alonso, Hortenia, Froiz, Iago Payo, García, Iago Rego, Peñas, Inmaculada Redondo, Pérez Sánchez, Javier R., García, Javier Tejada, Álvarez, Javier Villacieros, Domínguez, Jéssica Fernández, Etessam, Jesús Porta, Equiza, Jon, Pascual, Jorge Millán, Usieto, José Antonio Oliván, Reyes, José Antonio, Gómez, José Balseiro, Bueno, José Carlos Roche, Velasquez, Jose Luis Camacho, López, José María Barrios, Raquel Lamas, Leire Ainz, Lezama, Lidia Binela Lara, Caballero, Lorena, Davila, Lucía Galan, González, Nuria, de Antonio, Luis Alberto Rodríguez, Torres, Mª. Araceli García, Zabaleta, Maite Martinez, Rodríguez, Manuel Medina, Moragues, María Dolores, García, María Fuensanta Valero, Hernández, María, Abildúa, María José Abenza, Rabasa, María, Santos, María Rico, Usero, María, Zurdo, Martín, Más, Miguel, Maneiro, Miren, Platas, Montserrat González, Muriana, Nafría, Noelia González, Esteve, Oriol Barrachina, del Saz Saucedo, Pablo, Rocío, Vilar Ventura, Rosa M., Atienza, Saida, Navas, Sandra Rodríguez, Fernández, Santiago Fernández, Borja, Sergio, Navarro, Silvia Gil, García, Solange Kapetanovic, García, Susana, Salas, Teresa Mateos, Palasí, Toni, Cantero, Victoriano Romero, García-Azorín, David, Aguirre, María Elena Erro, Moncó, Juan Carlos García, Guijarro-Castro, Cristina, Delgado, Fernando Romero, Andrés, José Miguel Láinez, and Ezpeleta, David

Published
2021
Full Text
View/download PDF

26. Anosmia is associated with lower in-hospital mortality in COVID-19

Author

Talavera, Blanca, García-Azorín, David, Martínez-Pías, Enrique, Trigo, Javier, Hernández-Pérez, Isabel, Valle-Peñacoba, Gonzalo, Simón-Campo, Paula, de Lera, Mercedes, Chavarría-Miranda, Alba, López-Sanz, Cristina, Gutiérrez-Sánchez, María, Martínez-Velasco, Elena, Pedraza, María, Sierra, Álvaro, Gómez-Vicente, Beatriz, Guerrero, Ángel, and Arenillas, Juan Francisco

Published
2020
Full Text
View/download PDF

27. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study.

Author

Navarro-Pérez, María Pilar, González-Quintanilla, Vicente, Muñoz-Vendrell, Albert, Madrigal, Elisabet, Alpuente, Alicia, Latorre, Germán, Molina, Francis, Monzón, María José, Medrano, Vicente, García-Azorín, David, González-Oria, Carmen, Gago-Veiga, Ana, Velasco, Fernando, Beltrán, Isabel, Morollón, Noemí, Viguera, Javier, Casas-Limón, Javier, Rodríguez-Vico, Jaime, Cuadrado, Elisa, and Irimia, Pablo

Subjects
MIGRAINE, BOTULINUM A toxins, TERMINATION of treatment, TRAPEZIUS muscle, MUSCULAR atrophy
Abstract

Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting. Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability. Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longerterm exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues. Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.

Author

García-Azorín, David, Martínez-Badillo, Cristina, Camiña Muñiz, Javier, Gago-Veiga, Ana Beatriz, Morollón Sánchez, Noemi, González-Quintanilla, Vicente, Porta-Etessam, Jesús, Sierra-Mencía, Alvaro, González-García, Nuria, González-Osorio, Yésica, Polanco-Fernandez, Marcos, Recio-García, Andrea, Belvis Nieto, Robert, and Guerrero-Peral, Angel Luis

Subjects
*MEDICATION overuse headache, *MIGRAINE, *ANGIOTENSIN-receptor blockers, *CANDESARTAN
Abstract

Introduction: Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine. Methods: Observational, multicenter, prospective cohort study. The 50%, 75% and 30% responder rates, between weeks 8–12 and 20–24, were compared with the baseline. Treatment emergent adverse effects were systematically evaluated. Response predictors were estimated by multivariate regression models. Results: Eighty-six patients were included, 79.1% females, aged 39.5 (inter-quartile range [IQR] 26.3–50.3), with chronic migraine (43.0%), medication overuse headache (55.8%) and a median of two (inter-quartile range: 0.75–3) prior preventive treatments. At baseline patients had 14 (10–24) headache and 8 (5–11) migraine days per month. The 30%, 50% and 75% responder rates were 40%, 34.9% and 15.1% between weeks 8–12, and 48.8%, 36%, and 18.6% between weeks 20–24. Adverse effects were reported by 30 (34.9%) and 13 (15.1%) patients between weeks 0–12 and 12–24, leading to discontinuation in 15 (17.4%) patients. Chronic migraine, depression, headache days per month, medication overuse headache, and daily headache at baseline predicted the response between weeks 20–24. Conclusion: Candesartan effectiveness and tolerability in migraine prevention was in line with the clinical trials' efficacy. Trial registration: The study protocol is registered in ClinicalTrials.gov (NCT04138316). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine.

Author

Romero del Rincón, Celia, Gonzalez‐Martinez, Alicia, Quintas, Sonia, García‐Azorín, David, Fernández Lázaro, Iris, Guerrero‐Peral, Angel Luis, Gonzalez Osorio, Yesica, Santos‐Lasaosa, Sonia, González Oria, Carmen, Sánchez Rodríguez, Norberto, Iglesias Díez, Fernando, Echavarría Íñiguez, Ana, Gil Luque, Sendoa, Huerta‐Villanueva, Mariano, Campoy Díaz, Sergio, Muñoz‐Vendrell, Albert, Lozano Ros, Alberto, Sánchez‐Soblechero, Antonio, Velasco Juanes, Fernando, and Kortazar‐Zubizarreta, Izaro

Subjects
PEPTIDES, CALCITONIN gene-related peptide, MIGRAINE, TERMINATION of treatment, MONOCLONAL antibodies
Abstract

Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti‐CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti‐CGRP MAb (T‐baseline); last month of first treatment period (T‐suspension); month of restart due to worsening (T‐worsening); and 3 months after resumption (T‐reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T‐baseline was 20 (13) and MMD was 5 (6); at T‐suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T‐worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T‐reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti‐CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection

Author

García-Azorín, David, primary, Santana-López, Laura, additional, Lozano-Alonso, José Eugenio, additional, Ordax-Díez, Ana, additional, González-Osorio, Yésica, additional, Rojo-Rello, Silvia, additional, Eiros, José M, additional, Sánchez-Martínez, Javier, additional, Recio-García, Andrea, additional, Sierra-Mencía, Álvaro, additional, Sanz-Muñoz, Ivan, additional, and Guerrero-Peral, Ángel Luis, additional

Published
2023
Full Text
View/download PDF

31. Effectiveness, tolerability and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study

Author

Gonzalez-Martinez, Alicia, primary, Sanz-García, Ancor, additional, García-Azorín, David, additional, Rodriguez-Vico, Jaime Samuel, additional, Jaimes, Alex, additional, Gómez García, Andrea, additional, Casas Limón, Javier, additional, Díaz de Terán, Javier, additional, Sastre-Real, María, additional, Membrilla, Javier, additional, Latorre, Germán, additional, Calle de Miguel, Carlos, additional, Luque, Sendoa Gil, additional, Trevino-Peinado, Cristina, additional, Quintas, Sonia, additional, Heredia, Patricia, additional, Íñiguez, Ana Echavarría, additional, Guerrero-Peral, Ángel, additional, Sierra, Álvaro, additional, González-García, Nuria, additional, Porta-Etessam, Jesús, additional, and Gago-Veiga, Ana Beatriz, additional

Published
2023
Full Text
View/download PDF

35. Frequency and phenotype of headache in covid-19: a study of 2194 patients

Author

García-Azorín, David, Sierra, Álvaro, Trigo, Javier, Alberdi, Ana, Blanco, María, Calcerrada, Ismael, Cornejo, Ana, Cubero, Miguel, Gil, Ana, García-Iglesias, Cristina, Lozano, Ana Guiomar, Martínez Badillo, Cristina, Montilla, Carol, Mora, Marta, Núñez, Gabriela, Paniagua, Marina, Pérez, Carolina, Rojas, María, Ruiz, Marta, Sierra, Leticia, Hurtado, María Luisa, and Guerrero Peral, Ángel Luis

Published
2021
Full Text
View/download PDF

38. Self-reported periodontitis and migraine: results from a multicenter, cross-sectional survey in Spain

Author

Leira, Yago, Pozo-Rosich, Patricia, Torres-Ferrús, Marta, Orlandi, Marco, Láinez, José Miguel, Álvaro, Luis Carlos, Monzón, María José, Guerrero, Ángel, García-Azorín, David, Belvís, Roberto, González-Oria, Carmen, Gago-Veiga, Ana Beatriz, Latorre, Germán, Santos, Sonia, Cuadrado, María Luz, Blanco, Juan, Leira, Rogelio, and D’Aiuto, Francesco

Published
2019
Full Text
View/download PDF

39. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.

Author

Gonzalez-Martinez, Alicia, Sanz-García, Ancor, García-Azorín, David, Rodríguez-Vico, Jaime, Jaimes, Alex, García, Andrea Gómez, Casas-Limón, Javier, Terán, Javier Díaz de, Sastre-Real, María, Membrilla, Javier, Latorre, Germán, Miguel, Carlos Calle de, Luque, Sendoa Gil, Trevino-Peinado, Cristina, Quintas, Sonia, Heredia, Patricia, Echavarría-Íñiguez, Ana, Guerrero-Peral, Ángel, Sierra, Álvaro, and González-García, Nuria

Subjects
MIGRAINE prevention, THERAPEUTIC use of monoclonal antibodies, RESEARCH funding, CALCITONIN, DESCRIPTIVE statistics, PEPTIDES, ANALGESICS, DRUG efficacy, RESEARCH, CASE-control method, STATISTICS, PAIN management, COMPARATIVE studies, DRUG tolerance, MIGRAINE, EVALUATION, CHEMICAL inhibitors, SYMPTOMS, OLD age
Abstract

Objective To evaluate clinical characteristics, effectiveness, and tolerability of preventive anti- calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in the elderly. Anti-CGRP mAbs have demonstrated efficacy and safety in patients with migraine although there is limited information regarding the elderly. Design We performed a multicenter case-control study of cases (patients over 65 years old) and controls (sex-matched patients under 55 years old) with migraine receiving anti-CGRP mAbs. Methods We included the demographic characteristics, effectiveness—reduction in the number of monthly headache days (MHD) and monthly migraine days (MMD), 30%, 50%, and 75% responder rates—and treatment emergent adverse events (TEAEs). The primary endpoint was the 50% response rate regarding MHD at weeks 20–24; exploratory 50% response predictors in the elderly were evaluated. Results In total, 228 patients were included: 114 cases , 114 controls-. Among cases 84.2% (96/114) were women, 79.8% (91/114) CM; mean age of cases 70.1 years old (range: 66–86); mean age of controls was 42.9 years old(range: 38–49). Cases had a higher percentage of vascular risk factors (P  < .05),older age of onset (P  < .001) and more reported prior preventive treatments (P  < .001). Regarding effectiveness in cases, 50% response rate was achieved by 57.5% (42/73) at 20–24 weeks, with lower reduction in the MHD at 8–12 weeks (5 [7.2], 8 [9.1]; P  = .001) and a higher reduction in MMD at 20–24 weeks (10.7 [9.1], 9.2 [7.7]; P  = .04) compared to the control group. The percentage of TEAEs was similar in the 2 groups. Diagnosis of episodic migraine (EM) (P  = .03) and lower number of MHD at baseline (P  =.001) were associated with a 50% response in the elderly in univariate analysis. Conclusions Our study provides real world evidence of effectiveness and safety of anti-CGRP mAbs for migraine in patients without upper age-limit and possible predictors of anti-CGRP response in the elderly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Health equity, care access and quality in headache – part 1.

Author

Tana, Claudio, Raffaelli, Bianca, Souza, Marcio Nattan Portes, de la Torre, Elena Ruiz, Massi, Daniel Gams, Kisani, Najib, García-Azorín, David, and Waliszewska-Prosół, Marta

Subjects
MIGRAINE prevention, MEDICAL quality control, SOCIAL participation, CULTURE, HEALTH services accessibility, PAIN, SOCIAL determinants of health, CLINICAL governance, COVID-19, SOCIAL stigma, SYMPTOMS, QUALITY of life, HEADACHE, HEALTH equity
Abstract

Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient's features such as those related to an impaired quality of life, due to loss of social life and productivity, and the differences related to the geographical distribution of the disease and cultural misconceptions which tend to underestimate migraine as a psychosocial rather than neurobiological disorder. Global differences definition, care access, and health equity for headache disorders, especially migraine are reported in this paper from a collaborative group of the editorial board members of the Journal of Headache and Pain. Other components that affect patients with migraine, in addition to the impact promoted by the migraine symptoms such as stigma and social determinants, are also reported. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Long-term outcomes of nummular headache: A series of 168 patients and 1198 patient-years of follow-up

Author

García-Iglesias, Cristina, primary, González-Celestino, Ana, additional, Sierra Mencía, Álvaro, additional, González Osorio, Yésica, additional, Recio García, Andrea, additional, Martínez-Badillo, Cristina, additional, Echavarría Íñiguez, Ana, additional, Varona-Galán, Berta, additional, García-Azorín, David, additional, and Guerrero-Peral, Ángel Luis, additional

Published
2023
Full Text
View/download PDF

42. Multicentre Real-World Case-Control Study of Effectiveness, Tolerability, and Anti-Calcitonin Gene-Related Peptide Response Predictors in the Elderly

Author

Gonzalez-Martinez, Alicia, primary, Sanz-García, Ancor, additional, Rodríguez-Vico, Jaime Samuel, additional, Jaimes, Alex, additional, García, Andrea Gomez, additional, Limón, Javier Casas, additional, de Terán, Javier Díaz, additional, Sastre, María, additional, Membrilla, Javier, additional, Latorre, Germán, additional, de Miguel, Carlos Calle, additional, Quintas, Sonia, additional, Heredia, Patricia, additional, Luque, Sendoa Gil, additional, Trevino-Peinado, Cristina, additional, Echevarría, Ana, additional, García-Azorín, David, additional, Guerrero-Peral, Ángel Luis, additional, Álvaro Sierra, Álvaro Sierra, additional, González-García, Nuria, additional, Porta, Jesús, additional, and Gago-Veiga, Ana-Beatriz, additional

Published
2023
Full Text
View/download PDF

44. Connectivity-based Meta-Bands: A new approach for automatic frequency band identification in connectivity analyses

Author

Rodríguez-González, Víctor, primary, Núñez, Pablo, additional, Gómez, Carlos, additional, Shigihara, Yoshihito, additional, Hoshi, Hideyuki, additional, Miguel Ángel, Tola-Arribas, additional, Cano, Mónica, additional, Ángel, Guerrero, additional, García-Azorín, David, additional, Hornero, Roberto, additional, and Poza, Jesús, additional

Published
2023
Full Text
View/download PDF

45. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study

Author

Trigo, Javier, García-Azorín, David, Planchuelo-Gómez, Álvaro, Martínez-Pías, Enrique, Talavera, Blanca, Hernández-Pérez, Isabel, Valle-Peñacoba, Gonzalo, Simón-Campo, Paula, de Lera, Mercedes, Chavarría-Miranda, Alba, López-Sanz, Cristina, Gutiérrez-Sánchez, María, Martínez-Velasco, Elena, Pedraza, María, Sierra, Álvaro, Gómez-Vicente, Beatriz, Arenillas, Juan Francisco, and Guerrero, Ángel L.

Published
2020
Full Text
View/download PDF

50. Diferencias y similitudes entre la cefalea relacionada con la COVID-19 y la cefalea relacionada con la vacuna de la COVID-19. Un estudio de casos y controles

Author

González Celestino, Ana, primary, González Osorio, Yésica, additional, García Iglesias, Cristina, additional, Echavarría Iñiguez, Ana, additional, Sierra Mencía, Álvaro, additional, Recio García, Andrea, additional, Trigo López, Javier, additional, Planchuelo Gómez, Álvaro, additional, Hurtado, María Luisa, additional, Sierra Martínez, Leticia, additional, Ruiz, Marta, additional, Rojas Hernández, María, additional, Pérez Almendro, Carolina, additional, Paniagua, Marina, additional, Núñez, Gabriela, additional, Mora, Marta, additional, Montilla, Carol, additional, Martínez Badillo, Cristina, additional, Lozano Martínez, Ana Guiomar, additional, Gil, Ana, additional, Cubero, Miguel, additional, Cornejo, Ana, additional, Calcerrada, Ismael, additional, Blanco, María, additional, Alberdí Iglesias, Ana, additional, Fernández de las Peñas, César, additional, Guerrero Peral, Ángel Luis, additional, and García Azorín, David, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results